Barker D J, Weller R O, Garfield A J S. Epidemiology of primary tumours of the brain and spinal cord: A regional survey in Southern England[J]. Journal of Neurology Neurosurgery & Psychiatry, 1976, 39(3):290-296.
Baser M E, Friedman J M, Wallace A J, et al. Evaluation of clinical diagnostic criteria for neurofibromatosis 2.[J]. Neurology, 2002, 59(11):1759.
Bourn D, Carter S A, Mason S, et al. Germline mutations in the neurofibromatosis type 2 tumour suppressor gene[J]. Human Molecular Genetics, 1994, 3(5):813-6.
Cohen A, Modan B. Some epidemiologic aspects of neoplastic diseases in Israeli immigrant population. 3. Brain tumors.[J]. Cancer, 1969, 22(6):1323-1328.
Daniels R L, Swallow C, Shelton C, et al. Causes of unilateral sensorineural hearing loss screened by high-resolution fast spin echo magnetic resonance imaging: review of 1,070 consecutive cases[J]. American Journal of Otology, 2000, 21(2):173.
Evans D G R, Blair V, Strachan T, et al. Variation of expression of the gene for type 2 neurofibromatosis: absence of a gender effect on vestibular schwannomas, but confirmation of a preponderance of meningiomas in females[J]. Journal of Laryngology & Otology, 1995, 109(9):830.
Evans D G, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought[J]. Otology & Neurotology, 2005, 26(1):93.
Evans D G, Trueman L, Wallace A, et al. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.[J]. Journal of Medical Genetics, 1998, 35(6):450-5.
Frohlich A M, Sutherland G R. Epidemiology and clinical features of vestibular schwannoma in Manitoba, Canada[J]. Canadian Journal of Neurological Sciences, 1993, 20(2):126-30.
Gutmann D H, Aylsworth A, Carey J C, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA[J]. Jama the Journal of the American Medical Association, 1997, 278(1):51.
Hardell L, Hansson Mild K, Sandström M, et al. Vestibular schwannoma, tinnitus and cellular telephones.[J]. Neuroepidemiology, 2003, 22(2):124.
Howitz M F, Johansen C, Tos M, et al. Incidence of vestibular schwannoma in Denmark, 1977-1995.[J]. American Journal of Otology, 2000, 21(5):690-694.
Joensen P. Incidence of primary intracranial neoplasms in an isolated population (the Faroese) during the period 1962-1975.[J]. Acta Neurologica Scandinavica, 1981, 64(1):74-8.
Jukich P J, Mccarthy B J, Surawicz T S, et al. Trends in incidence of primary brain tumors in the United States, 1985-1994.[J]. Neuro-Oncology, 2001, 3(3):141.
Karjalainen S, Nuutinen J, Neittaanmäki H, et al. The incidence of acoustic neuroma in autopsy material.[J]. European Archives of Oto-Rhino-Laryngology, 1984, 240(1):91.
Kluwe L, Mautner V, Heinrich B, et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.[J]. Journal of Medical Genetics, 2003, 40(2):109.
Kurland L T. The frequency of intracranial and intraspinal neoplasms in the resident population of Rochester, Minnesota[J]. Journal of Neurosurgery, 1958, 15(6):627.
Lanser M J, Sussman S A, Frazer K. Epidemiology, pathogenesis, and genetics of acoustic tumors[J]. Otolaryngologic Clinics of North America, 1992, 25(3):499-520.
Lin D, Hegarty J L, Fischbein N J, et al. The prevalence of "incidental" acoustic neuroma.[J]. Archives of Otolaryngology - Head and Neck Surgery, 2005, 131(3):241-244.
Mérel P, Hoang-Xuan K, Sanson M, et al. Screening for germ-line mutations in the NF2 gene[J]. Genes Chromosomes Cancer, 1995, 12(2):117-27.
Mirz F, Jørgensen B G, Pedersen C B. [Vestibular schwannoma. Incidence of the disease and the consequences][J]. Ugeskrift for Laeger, 1998, 160(45):6516.
Moffat D A, Hardy D G, Irving R M, et al. Referral patterns in vestibular schwannomas.[J]. Clinical Otolaryngology & Allied Sciences, 2004, 29(5):515–517.
Moyhuddin A, Baser M E, Watson C, et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring.[J]. Journal of Medical Genetics, 2003, 40(6):459-63.
Mohyuddin A, Neary W J, Wallace A, et al. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas[J]. Journal of Medical Genetics, 2002, 39(5):315.
Anonymous. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.[J]. Archives of Neurology, 1988, 45(5):575-8.
Nestor J J, Korol H W, Nutik S L, et al. The incidence of acoustic neuromas.[J]. Arch Otolaryngol Head Neck Surg, 1988, 114(6):680.
Parry D M, Maccollin M M, Kaiser-Kupfer M I, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities[J]. American Journal of Human Genetics, 1996, 59(3):529-39.
Pettersson D, Mathiesen T, Prochazka M, et al. Long-term mobile phone use and acoustic neuroma risk[J]. Epidemiology, 2014, 25(2):233-41.
Prestonmartin S, Thomas D C, Wright W E, et al. Noise trauma in the aetiology of acoustic neuromas in men in Los Angeles County, 1978-1985[J]. British Journal of Cancer, 1989, 59(5):783-6.
Propp J M, Mccarthy B J, Davis F G, et al. Descriptive epidemiology of vestibular schwannomas.[J]. Neuro-oncology, 2006, 8(1):1.
Ruggieri M, Huson S M. The clinical and diagnostic implications of mosaicism in the neurofibromatoses.[J]. Neurology, 2001, 56(11):1433-43.
Ruttledge M H, Andermann A A, Phelan C M, et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease[J]. American Journal of Human Genetics, 1996, 59(2):331.
Schoenberg B S, Christine B W, Whisnant J P. The descriptive epidemiology of primary intracranial neoplasms: the Connecticut experience[J]. American Journal of Epidemiology, 1976, 104(5):499-510.
Selesnick S, Deora M M, Heier L. Incidental discovery of acoustic neuromas.[J]. Otolaryngol Head Neck Surg, 1999, 120(6):815-818.
Sutherland G R, Florell R, Louw D, et al. Epidemiology of primary intracranial neoplasms in Manitoba, Canada.[J]. Canadian Journal of Neurological Sciences, 1987, 14(4):586-592.
Szyfter W, Kopeć T. [Epidemiology of acoustic neuromas in Poland][J]. Otolaryngologia polska = The Polish otolaryngology, 2001, 55(5):533.
Thomsen J, Tos M. Acoustic neuromas. Diagnostic delay, growth rate and possible non-surgical treatment.[J].  1988, 452(s452):26-33.
Tos M, Charabi S, Thomsen J. Clinical experience with vestibular schwannomas: epidemiology, symptomatology, diagnosis, and surgical results[J]. European Archives of Oto-Rhino-Laryngology, 1998, 255(1):1-6.
Mirko Tos Md  Dmsc, Samih Charabi Md  Dmsc, Jens Thomsen Md  Dmsc. Incidence of vestibular schwannomas[J]. Laryngoscope, 1999, 109(5):736–740.
Tos M, Stangerup S E, Cayéthomasen P, et al. What Is the Real Incidence of Vestibular Schwannoma?[J]. Archives of otolaryngology--head & neck surgery, 2004, 130(2):216-220.
Tos M, Thomsen J, Charabi S. Incidence of Acoustic Neuromas[J]. Ear Nose & Throat Journal, 1994, 71(9):391-393.
Tos M, Thomsen J. Epidemiology of acoustic neuromas[J]. Journal of Laryngology & Otology, 1984, 98(7):685-692.
Bederson J B, Von A K, Wichmann W W, et al. Conservative treatment of patients with acoustic tumors[J]. Neurosurgery, 1991, 28(5):646-650.
Bozorg G A, Kalamarides M, Ferrary E, et al. Conservative management versus surgery for small vestibular schwannomas.[J]. Acta Oto-Laryngologica, 2005, 125(10):1063-1068.
Per Caye-Thomasen MD  DMSc, Søren Hansen M D, Thomas Dethloff M D, et al. Sublocalization and Volumetric Growth Pattern of Intracanalicular Vestibular Schwannomas[J]. Laryngoscope, 2006, 116(7):1131-5.
Cayé-Thomasen P, Werther K, Nalla A, et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate[J]. Otology & Neurotology, 2005, 26(1):98-101.
Charabi S, Tos M, Børgesen S E, et al. Cystic acoustic neuromas. Results of translabyrinthine surgery.[J]. Archives of otolaryngology--head & neck surgery, 1994, 120(12):1333.
Charabi S, Tos M, Thomsen J, et al. Cystic Vestibular Schwannoma - Clinical and Experimental Studies[J].  2000, 543(537):11-13.
Wallace C J, Fong T C, Auer R N. Cystic intracranial schwannoma.[J]. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 1993, 44(6):453.
Charabi S. Acoustic neuroma/vestibular schwannoma in vivo and in vitro growth models. A clinical and experimental study.[J]. Acta oto-laryngologica. Supplementum, 2009, 530(s530):1-27.
Diensthuber M, Ilner T, Rodt T, et al. Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression.[J]. Otology & Neurotology, 2007, 28(4):559-565.
Drapkin A J, Rose W S. Multicystic acoustic neuroma. Case report and differential diagnosis[J]. Acta Radiologica, 1989, 30(1):7-9.
Fundová P, Charabi S, Tos M, et al. Cystic vestibular schwannoma: surgical outcome[J]. Journal of Laryngology & Otology, 2000, 114(12):935-939.
Gomez-Brouchet A, Delisle M B, Cognard C, et al. Vestibular schwannomas: correlations between magnetic resonance imaging and histopathologic appearance[J].  2001, 22(1):79-86.
Huo Z, Zhang Z, Qi H, et al. Clinical comparison of two subtypes of cystic vestibular schwannoma: surgical considerations and outcomes[J]. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2016, 273(12):4215.
Laasonen E M, Troupp H. Volume growth rate of acoustic neurinomas[J]. Neuroradiology, 1986, 28(3):203-7.
Lee K S, Nagashima T, Cho K G, et al. The proliferative activity of neurilemomas ☆[J]. Surgical Neurology, 1989, 32(6):427-33.
Linthicum F H, Saleh E S, Hitselberger W E, et al. Growth of Postoperative Remnants of Unilateral Vestibular Nerve Schwannoma: Role of the Vestibular Ganglion[J]. Orl J Otorhinolaryngol Relat Spec, 2002, 64(2):138-142.
Lunardi P, Missori P, Mastronardi L, et al. Cystic Acoustic Schwannomas[J]. Acta Neurochirurgica, 1991, 110(3-4):120-123.
Matthies C, Samii M, Krebs S. Management of vestibular schwannomas (acoustic neuromas): radiological features in 202 cases--their value for diagnosis and their predictive importance[J]. Neurosurgery, 1997, 40(3):481-2.
Meyer T A, Canty P A, Wilkinson E P, et al. Small Acoustic Neuromas: Surgical Outcomes Versus Observation or Radiation[J]. Otology & Neurotology, 2006, 27(3):380-392.
Moon K S, Jung S, Seo S K, et al. Cystic vestibular schwannomas: a possible role of matrix metalloproteinase-2 in cyst development and unfavorable surgical outcome.[J]. Journal of Neurosurgery, 2007, 106(5):866.
Muzumdar D P, Goel A, Pakhmode C K. Multicystic acoustic neurinoma: report of two cases[J]. Journal of Clinical Neuroscience, 2002, 9(4):453-455.
Park C K, Jung H W, Kim J E, et al. Therapeutic strategy for large vestibular schwannomas[J]. Journal of Neuro-Oncology, 2006, 77(2):167.
Park C K, Kim D C, Park S H, et al. Microhemorrhage, a possible mechanism for cyst formation in vestibular schwannomas[J]. Journal of Neurosurgery, 2006, 105(4):576-580.
Pendl G, Ganz J C, Kitz K, et al. Acoustic Neurinomas with Macrocysts Treated with Gamma Knife Radiosurgery[J]. Stereotactic & Functional Neurosurgery, 1997, 66 Suppl 1(1):103-111.
Perneczky A. Blood supply of acoustic neurinomas[J]. Acta Neurochirurgica, 1980, 52(3-4):209-218.
Piccirillo E, Wiet M R, Flanagan S, et al. Cystic vestibular schwannoma: classification, management, and facial nerve outcomes[J]. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2009, 30(6):826.
Prakash G S. Multicystic Acoustic Neuroma[J]. Acta Radiologica, 1990, 31(1):112.
Schmerber S, Palombi O, Boubagra K, et al. Long-term control of vestibular schwannoma after a translabyrinthine complete removal.[J]. Neurosurgery, 2005, 57(4):693-8.
Jr T J. Supplementary comment on "optimal extent of resection in vestibular schwannoma surgery: relationship to recurrence and facial nerve preservation".[J]. Neurologia medico-chirurgica, 2006, 46(6):176.
Selesnick S H, Johnson G. Radiologic surveillance of acoustic neuromas[J]. American Journal of Otology, 1998, 19(6):846.
Yoshimoto Y. Systematic review of the natural history of vestibular schwannoma[J]. Journal of Neurosurgery, 2005, 103(1):59.
Zhang Z, Wang Z, Sun L, et al. Mutation spectrum and differential gene expression in cystic and solid vestibular schwannoma.[J]. Genetics in Medicine Official Journal of the American College of Medical Genetics, 2014, 16(3):264-70.
Zhang Z, Wang Z, Huang Q, et al. Removal of Large or Giant Sporadic Vestibular Schwannomas via Translabyrinthine Approach: A Report of 115 Cases[J]. ORL J Otorhinolaryngol Relat Spec.  2012, 74(5):271-277.
Alfthan K, Heiska L, Grönholm M, et al. Cyclic AMP-dependent Protein Kinase Phosphorylates Merlin at Serine 518 Independently of p21-activated Kinase and Promotes Merlin-Ezrin Heterodimerization[J]. The Journal of biological chemistry, 2004, 279(18):18559-66.
Bai Y, Liu Y J, Wang H, et al. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin.[J]. Oncogene, 2007, 26(6):836.
Bashour A M, Meng J J, Ip W, et al. The Neurofibromatosis Type 2 Gene Product, merlin, Reverses the F-Actin Cytoskeletal Defects in Primary Human Schwannoma Cells[J]. Molecular & Cellular Biology, 2002, 22(4):1150.
Bikhazi N B, Lalwani A K, Jackler R K, et al. Familial occurrence of unilateral vestibular schwannoma.[J]. Laryngoscope, 1997, 107(9):1176-80.
Bono P, Cordero E, Johnson K, et al. Layilin, a cell surface hyaluronan receptor, interacts with merlin and radixin.[J]. Experimental Cell Research, 2005, 308(1):177-187.
C Bovie, S Holden, A Schroer, E Smith, D Trump, F Raymond. Neurofibromatosis 2 in a patient with a de novo balanced reciprocal translocation 46,X,t(X;22)(p11.2;q11.2)[J]. Journal of Medical Genetics, 2003, 40(9):682-4.
蔡丽慧, 吴皓, 吕静荣,等. 听神经瘤S518磷酸化Merlin蛋白的表达及与CD44结合特性[J]. 中华耳鼻咽喉头颈外科杂志, 2008, 43(12):910-914.
陈洁, 吴皓, 向明亮. 听神经瘤的分子生物学研究进展[J]. 中国耳鼻咽喉颅底外科杂志, 2006, 12(1):77-80.
Gutmann D H, Sherman L, Seftor L, et al. Increased Expression of the NF2 Tumor Suppressor Gene Product, Merlin, Impairs Cell Motility, Adhesion and Spreading[J]. Human Molecular Genetics, 1999, 8(2):267.
Fehon R G. Phosphorylation and Activity of the Tumor Suppressor Merlin and the ERM Protein Moesin Are Coordinately Regulated by the Slik Kinase[J]. Journal of Cell Biology, 2006, 175(2):305.
Jacoby L B, Maccollin M, Louls D N, et al. Exon scanning for mutation of the NF2 gene in schwannomas[J]. Human Molecular Genetics, 1994, 3(3):413.
Jin H, Sperka T, Herrlich P, et al. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase[J]. Nature, 2006, 442(7102):576.
Jung J R, Kim H, Jeun S S, et al. The Phosphorylation status of merlin is important for regulating the Ras-ERK pathway.[J]. Molecules & Cells, 2005, 20(2):196-200.
Kim H, Kwak N J, Lee J Y, et al. Merlin Neutralizes the Inhibitory Effect of Mdm2 on p53[J]. Journal of Biological Chemistry, 2004, 279(9):7812.
Kissil J L, Johnson K C, Eckman M S, et al. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization.[J]. Journal of Biological Chemistry, 2002, 277(12):10394.
Kluwe L, Mautner V, Heinrich B, et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.[J]. Journal of Medical Genetics, 2003, 40(2):109.
Knudson A G. Mutation and cancer: statistical study of retinoblastoma.Proc. Natl. Acad. Sci. USA 68:820-823[J]. Proceedings of the National Academy of Sciences, 1971, 68(4):820-823.
Lee H, Kim D, Dan H C, et al. Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein.[J]. Molecular & Cellular Biology, 2007, 27(6):2103-19.
Lü J, Zou J, Wu H, et al. Compensative shuttling of merlin to phosphorylation on serine 518 in vestibular schwannoma[J]. Laryngoscope, 2008, 118(1):169.
吕静荣, 吴皓. 听神经瘤分子生物学研究[J]. 国际耳鼻咽喉头颈外科杂志, 2006, 30(1):49-52.
吕静荣, 邹静, 吴皓. Merlin蛋白在听神经瘤组织中的表达与分布[J]. 中华耳鼻咽喉头颈外科杂志, 2006, 41(7):501-505.
Manchanda N, Lyubimova A, Ho H Y, et al. The NF2 tumor suppressor Merlin and the ERM proteins interact with N-WASP and regulate its actin polymerization function[J]. Journal of Biological Chemistry, 2005, 280(13):12517-22.
Mcclatchey A I, Saotome I, Mercer K, et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors.[J]. Genes & Development, 1998, 12(8):1121.
Morrison H, Sherman L S, Legg J, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44[J]. Genes & Development, 2001, 15(8):968-80.
Morrison H, Sperka T, Manent J, et al. Merlin/Neurofibromatosis Type 2 Suppresses Growth by Inhibiting the Activation of Ras and Rac[J]. Cancer Research, 2007, 67(2):520-7.
Muranen T, Grönholm M, Renkema G H, et al. Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin.[J]. Oncogene, 2005, 24(7):1150-1158.
Neill G W, Crompton M R. Binding of the merlin-I product of the neurofibromatosis type 2 tumour suppressor gene to a novel site in beta-fodrin is regulated by association between merlin domains.[J]. Biochemical Journal, 2001, 358(Pt 3):727-735.
Pearson M A, Reczek D, Bretscher A, et al. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain.[J]. Cell, 2000, 101(3):259.
Ramesh V. Merlin and the ERM proteins in Schwann cells, neurons and growth cones.[J]. Nature Reviews Neuroscience, 2004, 5(6):462-470.
Rangwala R, Banine F, Borg J P, et al. Erbin regulates mitogen-activated protein (MAP) kinase activation and MAP kinase-dependent interactions between Merlin and adherens junction protein complexes in Schwann cells.[J]. Journal of Biological Chemistry, 2005, 280(12):11790-7.
Rouleau G A, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.[J]. Nature, 1993, 363(6429):515-21.
Rouleau G A, Wertelecki W, Haines J L, et al. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22[J]. Nature, 1987, 329(6136):246.
Schulze K M, Hanemann C O, Müller H W, et al. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis.[J]. Human Molecular Genetics, 2002, 11(1):69-76.
Seizinger B R, Martuza R L, Gusella J F. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma[J]. Nature, 1986, 322(6080):644-647.
Shaw R J, Mcclatchey A I, Jacks T. Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli[J]. Journal of Biological Chemistry, 1998, 273(13):7757-64.
Shimizu T, Seto A, Maita N, et al. Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain.[J]. Journal of Biological Chemistry, 2002, 277(12):10332.
Speck O, Hughes S C, Noren N K, et al. Moesin functions antagonistically to the Rho pathway to maintain epithelial integrity[J]. Nature, 2003, 421(6918):83.
Stokowski R P, Cox D R. Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations.[J]. American Journal of Human Genetics, 2000, 66(3):873-91.
Sun C X, Robb V A, Gutmann D H. Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation[J]. Journal of Cell Science, 2002, 115(21):3991-4000.
Surace E I, Haipek C A, Gutmann D H. Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function[J]. Oncogene, 2004, 23(2):580-587.
Trofatter J A, Maccollin M M, Rutter J L, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor[J]. Cell, 1993, 75(4):826.
Tsilchorozidou T, Menko F H, Lalloo F, et al. Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2[J]. Journal of Medical Genetics, 2004, 41(7):529-34.
Wang Z, Lu Y, Tang J, et al. The phosphorylation status of merlin in sporadic vestibular Schwannomas.[J]. Molecular and Cellular Biochemistry, 2009, 324(1):201-206.
Xiao G H, Beeser A, Chernoff J, et al. p21-activated kinase links Rac/Cdc42 signaling to merlin[J]. Journal of Biological Chemistry, 2002, 277(2):883-6.
Xiao G H, Gallagher R, Shetler J, et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.[J]. Molecular & Cellular Biology, 2005, 25(6):2384.
Zang K D. Cytological and cytogenetic studies on human meningioma[J]. Cancer Genetics & Cytogenetics, 1982, 6(3):249-274.
Zucman-Rossi J, Legoix P, Der S H, et al. NF2 gene in neurofibromatosis type 2 patients[J]. Human Molecular Genetics, 1998, 7(13):2095-101.
Wuttipong T, Helmut B. Loss of heterozygosity on chromosome 22 in sporadic schwannoma and its relation to the proliferation of tumor cells[J]. 中华医学杂志(英文版), 2005, 118(18):1517-1524.
Vincent Darrouzet M D, Jacques Martel M D, Véronique Enée M D, et al. Vestibular Schwannoma Surgery Outcomes: Our Multidisciplinary Experience in 400 Cases Over 17 Years[J]. Laryngoscope, 2004, 114(4):681–688.
Feiz-Erfan I, Zabramski J M, Herrmann L L, et al. Cavernous malformation within a schwannoma: review of the literature and hypothesis of a common genetic etiology[J]. Acta Neurochirurgica, 2006, 148(6):647-652.
Francovidal V, Songu M, Blanchet H, et al. Intracochlear hemorrhage after gamma knife radiosurgery.[J]. Otology & neurotology, 2007, 28(2):240-244.
Kim S H, Youm J Y, Song S H, et al. Vestibular schwannoma with repeated intratumoral hemorrhage.[J]. Clin Neurol Neurosurg, 1998, 100(1):68-74.
Park C K, Kim D C, Park S H, et al. Microhemorrhage, a possible mechanism for cyst formation in vestibular schwannomas[J]. Journal of Neurosurgery, 2006, 105(4):576-580.
Sakata H, Fujimura M, Watanabe M, et al. Association of cavernous malformation within vestibular schwannoma: immunohistochemical analysis of matrix metalloproteinase-2 and -9[J]. Neurologia medico-chirurgica, 2007, 47(11):509.
Vellin J F, Bozorg G A, Kalamarides M, et al. Intratumoral and brainstem hemorrhage in a patient with vestibular schwannoma and oral anticoagulant therapy[J]. Ontology & Neurotology, 2006, 27(2):209-212.
卞留贯, 殷玉华, 沈建康,等. 囊性听神经瘤[J]. 中国微侵袭神经外科杂志, 2001, 6(1):30-33.
黄选兆. 《实用耳鼻咽喉头颈外科学》第2版[J]. 中国医学文摘:耳鼻咽喉科学, 2008(4):237-237.
弗莱彻. 肿瘤组织病理诊断[M]. 山东科学技术出版社, 2001.